New data presented at ASTRO 2026 show Artera’s multimodal AI prostate cancer biomarker delivers consistent prognostic results across diverse patient populations, supporting its use in personalized treatment decisions, according to five abstracts.
Read More
A Stanford-led study found that Resero Bio’s uRARE-seq urine cfRNA test can non-invasively detect bladder cancer, assess tumor grade, and predict therapy response in 683 patient samples.
Read More
Using microfluidic shear stress, the system detaches living cells from excised tissue to support pathology workflows and downstream diagnostic testing.
Read More
Project HOPE, funded by The Labcorp Charitable Foundation, has launched a two-year Madison, Wisconsin, initiative with local clinics to expand PSA testing and prostate cancer care for uninsured men facing access barriers.
Read More
Early data from a new pathology institute in Reutlingen, Germany, revealed that referral networks and case mix stabilized quickly, with urology comprising up to 61.8% of cases among 2,114 reviewed in the first six months.
Read More